Bright Minds BiosciencesDRUG
About: Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
76,659% more capital invested
Capital invested by funds: $230K [Q3] → $176M (+$176M) [Q4]
2,400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 1
400% more funds holding
Funds holding: 6 [Q3] → 30 (+24) [Q4]
76.25% more ownership
Funds ownership: 4.29% [Q3] → 80.54% (+76.25%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 187 met price target | 149%upside $85 | Buy Reiterated | 19 Feb 2025 |
Financial journalist opinion









